sábado, 21 de noviembre de 2026
The grim human cost of the Trump—RFK Jr. measles-prevention failure: 16 times more cases than in 2024 Mauro Proença | November 19, 2026
https://geneticliteracyproject.org/2026/11/19/the-grim-human-cost-of-the-trump-rfk-jr-measles-prevention-failure-16-times-more-cases-than-in-2024/
Measles was once a public health success story, eliminated from the United States more than a quarter-century ago. Now, with cases surging, vaccination rates falling, and the loss of the nation’s elimination status, a preventable disease is making an unwelcome comeback. The question is no longer simply why parents hesitate to vaccinate, but whether misinformation, institutional distrust, and conflicting messages from public health leaders are making that hesitation harder to overcome.
Health vs. Hype’s rocky debut: American Medical Association’s misinformation-debunking podcast platforms ‘leaky gut’ wellness crank MedPage Today | November 19, 2026
https://geneticliteracyproject.org/2026/11/19/health-vs-hypes-rocky-debut-american-medical-associations-misinformation-debunking-podcast-platforms-leaky-gut-wellness-crank/
The American Medical Association has finally stepped into the misinformation ring with its new podcast, Health vs. Hype — but its gut-health episode left many in the scientific community scratching their heads, Katie Suleta argues in an opinion piece for MedPage Today.
The show has taken on creatine, protein-maxxing and detoxes, which the author calls “a long-overdue and vital institutional response.” In late October, though, host Trace Dominguez interviewed Danielle Brown, a nutrition influencer and self-described holistic nutritionist, for an episode on sea moss, leaky gut and probiotics. Gastroenterologist Mohamed Mokadem, MD, then joined to address her claims.
Why should thousands of Americans die every year waiting for a kidney transplant? There’s an easy fix to this morbid reality Wall Street Journal | November 19, 2026
https://geneticliteracyproject.org/2026/11/19/why-should-thousands-of-americans-die-every-year-waiting-for-a-kidney-transplant-theres-an-easy-fix-to-this-morbid-reality/
Legally rewarding living kidney donors through the tax code could shrink a waiting list that kills roughly 12 Americans a day, argues psychiatrist Sally Satel in an opinion piece for The Wall Street Journal. Satel speaks from experience: friends donated kidneys to her in 2006 and 2016.
Living donors account for about 1 in 3 kidney recipients. Everyone else depends on the national waiting list run by the United Network for Organ Sharing (UNOS), which has never met demand. When Satel got her first kidney, about 70,000 other patients were still waiting.
Viewpoint: The dangerous lie RFK Jr.-founded Children’s Health Defense is circulating to discredit one of medicine’s great breakthroughs: the MMR (measles-mumps-rubella) vaccine Stop AntiVax Propaganda | November 19, 2026
https://geneticliteracyproject.org/2026/11/19/viewpoint-the-dangerous-lie-rfk-jr-founded-childrens-health-defense-is-circulating-to-discredit-one-of-medicines-great-breakthroughs-the-mmr-measles-mumps-rubella-vaccine/
Not surprisingly, with the announcement of yet another measles death, as if on cue, Children’s Health Defense is spreading another myth about MMR vaccine deaths.
Crunchy Moms disinformation flood: Zuckerberg’s Facebook has opened floodgates on measles and vaccines The Guardian | November 20, 2026
https://geneticliteracyproject.org/2026/11/20/crunchy-moms-disinformation-flood-zuckerbergs-facebook-has-opened-floodgates-on-measles-and-vaccines/
Facebook isn’t just tolerating dangerous vaccine misinformation in its groups — it’s steering users toward it, as The Guardian’s Michelle R Smith reports. Her investigation centers on Crunchy Moms, a public group of more than 490,000 members where commenters routinely call vaccines “poison” and insist they cause autism and sudden infant death syndrome (SIDS).
The stakes aren’t abstract. When a Lancaster County, Pennsylvania, parent asked in August whether to vaccinate their three-year-old during a measles outbreak, members replied that children “cannot die of measles.” Pennsylvania has reported six measles-associated deaths this year, including two babies in Lancaster County. Meta’s own AI then summarized the 589 replies, noting commenters “claim the vaccine is unnecessary or even harmful.”
US initiative targets $200M to accelerate therapeutic cancer vaccines The National Cancer Institute and Foundation for the NIH are seeking $200 million to support clinical trials, develop new vaccine platforms, and build a shared data resource. Written byBree Foster, PhD
US initiative targets $200M to accelerate therapeutic cancer vaccines
The National Cancer Institute and Foundation for the NIH are seeking $200 million to support clinical trials, develop new vaccine platforms, and build a shared data resource.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/us-initiative-targets-200m-to-accelerate-therapeutic-cancer-vaccines-17676
On November 11th, data from the INTerpath-001 Phase 3 trial provided the first clinical evidence that a personalized mRNA cancer vaccine can improve outcomes when combined with immunotherapy. The encouraging results have prompted a new US public–private initiative to accelerate the development of therapeutic cancer vaccines across multiple tumor types.
The National Cancer Institute (NCI) and the Foundation for the National Institutes of Health (FNIH) are establishing a $200 million Therapeutic Cancer Vaccines Initiative (TCVI) to advance promising vaccine candidates into clinical testing.
Pfizer steps into in vivo CAR T space with $2.6B licensing deal FDA approvals, trial updates, and more led the news this week. Brought to you byDDN editorial team
Pfizer steps into in vivo CAR T space with $2.6B licensing deal
FDA approvals, trial updates, and more led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/weekly-rundown-pfizer-steps-into-in-vivo-car-t-space-with-2-6b-licensing-deal-17675
On Wednesday, Pfizer announced an exclusive licensing deal with Starna Therapeutics, giving Pfizer the rights to three in vivo pre-IND CAR-T autoimmune programs. Under the agreement, Starna will receive an upfront payment of $330 million, with the potential to earn up to $2.3 billion in milestone payments and royalties on net sales of any approved products. The deal comes amidst a flood of patents that will expire for Pfizer in the next few years, and marks Pfizer’s first foray into the in vivo CAR-T space. “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches,” said Michael Vincent, Chief Inflammation & Immunology Officer at Pfizer, in the press release. – Allison Whitten
Suscribirse a:
Entradas (Atom)

